Daclacure 60mg (Daclatasvir Dihydrocloride ) is the first-in-class NS5A inhibitor used in combination with Sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection. As Compared to other treatment options, this combination not only increases the cure rate, but is also regarded as a valuable treatment option in some of the difficult-to-treat HCV patient subsets.
Mode Of Action
Daclacure 60mg Tablet is an antiviral medication. Daclacure works by lowering a load of hepatitis C virus in the body and removing the virus from the blood over a period of time.
Side Effect Of Daclacure 60mg Tablet
• Insomnia (difficulty in sleeping)
• Anemia (low number of red blood cells)
Dosage and Administration
The recommended dosage in most people is one 60mg tablet taken each day. The tablet is taken orally and should be swallowed whole with a glass of water. Daclacure can be taken with or without food.
Treatment with Daclacure 60mg (Daclatasvir Dihydrochloride) is usually prescribed for a period of 12 weeks.
Daclacure 60mg should always be taken concurrently with Sofosbuvir.
Daclacure should be taken with Sofosbuvir and Ribavarin in the following cases:
- Genotype 1 infection with decompensated cirrhosis
- Genotype 1 infection post-transplant
- Genotype 3 infections with compensated cirrhosis or decompensated cirrhosis
- Genotype 3 infection post-transplant
The most common side effects associated with Daclacure 60mg (Daclatasvir Dihydrochloride) and Sofosbuvir treatment are headache, fatigue, nausea and diarrhea.
When Daclacure 60mg is taken with Sofosbuvir and Ribavirin people also report anemia, rash, insomnia, dizziness and somnolence as side effects.
Daclacure 60mg (Daclatasvir Dihydrochloride) is a treatment for chronic hepatitis C virus (HCV) genotype 1 or genotype 3 infection. It is prescribed with sofosbuvir, and with or without ribavirin.
Store at a temperature of no higher than 25 degrees in a dry, protected area.
Do not take it after the expiration date